Sign in →

Test ID SMAT Smooth Muscle Antibody Titer, Serum


Specimen Required


Only orderable as part of a reflex. For more information see SMAS / Smooth Muscle Antibody Screen, Serum.

 

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.8 mL

Collection Instructions: Centrifuge and aliquot serum into plastic vial


Secondary ID

608956

Useful For

Antibody titer testing as a part of evaluating patients with chronic liver disease in whom the diagnosis of chronic active autoimmune hepatitis is suspected

Testing Algorithm

If the smooth muscle antibody (SMA) screen is equivocal or positive, then the SMA titer will be performed at an additional charge.

Method Name

Only orderable as part of a reflex. For more information see SMAS / Smooth Muscle Antibody Screen, Serum.

 

Indirect Immunofluorescence

Reporting Name

Smooth Muscle Ab Titer, S

Specimen Type

Serum

Specimen Minimum Volume

0.4 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Clinical Information

Autoimmune hepatitis (AIH) is caused by chronic inflammation within the liver, resulting in damage to the hepatocytes.(1) Initially, patients with AIH may be clinically asymptomatic, usually identified only through an incidental finding of abnormal liver function tests. At a more advanced stage, patients may manifest with symptoms such as jaundice, pruritus, or ascites, which are secondary to the more extensive liver damage. As implied by the name, AIH has many characteristics of an autoimmune disease, including female predominance, hypergammaglobulinemia, association with specific HLA alleles, responsiveness to immunosuppression, and the presence of autoantibodies. There are several autoantibodies associated with AIH, although the most common are smooth muscle antibodies (SMA). SMA are generally identified by indirect immunofluorescence using a smooth muscle substrate. The antigen specificity of SMA in the context of AIH has been identified as filamentous-actin (F-actin).(2) Because the clinical symptoms of AIH are nonspecific, being found in a variety of liver diseases (drug/alcohol-associated hepatitis, viral hepatitis, primary sclerosing cholangitis, etc), the diagnosis can be challenging. A set of diagnostic criteria for AIH has been published and includes the presence of various autoantibodies, elevated total IgG, evidence of hepatitis on liver histology, and absence of viral markers.(3) The combination of autoantibody serology, specifically SMA and anti-F-actin antibodies, with liver histology and thorough clinical evaluation are useful in the evaluation of patients with suspected autoimmune hepatitis.

Reference Values

Only orderable as part of a reflex. For more information see SMAS / Smooth Muscle Antibody Screen, Serum.

 

Negative

Reference values apply to all ages.

Cautions

Serologic tests for autoantibodies, including smooth muscle antibodies (SMA), should not be relied upon exclusively to determine the etiology or prognosis of patients with liver disease.

 

A positive result for SMA may occur in patients who do not have autoimmune hepatitis. A negative result does not exclude a diagnosis of autoimmune hepatitis.

Day(s) Performed

Monday through Saturday

Report Available

2 to 4 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86015

NY State Approved

Yes